Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Ariad Pharmaceuticals, Inc.    ARIA   US04033A1007

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/17/2014 07/18/2014 07/21/2014 07/22/2014 07/23/2014 Date
5.0099(c) 5.2(c) 5.15(c) 5.1(c) 5.2377 Last
12 052 567 6 781 035 3 386 709 5 159 907 183 904 Volume
-6.71% +3.79% -0.96% -0.97% +2.70% Change
More quotes
Company
ARIAD Pharmaceuticals, Inc. operates as a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company has four products: Ridaforolimus, Ponatinib, AP1903 and AP26113. Its approach to structure-based drug... 
Sector
Pharmaceuticals
Calendar
08/06Earnings Release
Surperformance© rating of Ariad Pharmaceuticals, Inc
Trading Rating : Investor Rating :
More about the company
Chart ARIAD PHARMACEUTICALS, INC
Duration : Period :
Ariad Pharmaceuticals, Inc Technical Analysis Chart | ARIA | US04033A1007 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 82,6 M
EBIT 2014 -197 M
Net income 2014 -195 M
Finance 2014 169 M
Yield 2014 -
Sales 2015 162 M
EBIT 2015 -131 M
Net income 2015 -126 M
Finance 2015 142 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 9,59x
EV / Sales 2015 5,07x
Capitalization 962 M
More Financials
Latest news on ARIAD PHARMACEUTICALS, INC
5d ago ARIAD PHARMACEUTICALS : Assigned Patent
6d ago ARIAD PHARMACEUTICALS : Thursday's ETF Movers: GDXJ, XBI
07/16 ARIAD PHARMACEUTICALS : to Webcast Conference Call on Second Quarter 2014 Financ..
07/14 ARIAD PHARMACEUTICALS : Announces Continuation of Iclusig Review under the Artic..
07/02 ARIAD PHARMACEUTICALS : Researchers Submit Patent Application, "Methods and Comp..
06/28 ARIAD PHARMACEUTICALS : Bolsters Its Global Management Team with 3 Recent Appoin..
06/26 ARIAD PHARMACEUTICALS : Change in Directors or Principal Officers, Submission of..
06/26 ARIAD PHARMACEUTICALS : Strengthens Its Global Management Team with 3 Recent App..
06/24 ARIAD PHARMACEUTICALS : Entry into a Material Definitive Agreement, Financial St..
06/23 ARIAD PHARMACEUTICALS : Announces Three Key Appointments to Its Global Managemen..
06/22 ARIAD PHARMACEUTICALS : Proposes $175 Million Offering of Convertible Senior Not..
06/19 ARIAD PHARMACEUTICALS : Other Events, Financial Statements and Exhibits (form 8-..
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
Ariad Pharmaceuticals, Inc : Income Statement Evolution
More Financials
EPS Revisions
Ariad Pharmaceuticals, Inc : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF